These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30791097)

  • 1. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
    Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
    Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cell-free DNA levels are a useful marker for extramammary Paget disease.
    Mijiddorj T; Kajihara I; Tasaki Y; Otsuka-Maeda S; Sakamoto R; Sawamura S; Kanazawa-Yamada S; Egashira S; Inoue K; Makino K; Miyashita A; Aoi J; Igata T; Makino T; Masuguchi S; Fukushima S; Jinnin M; Morinaga J; Ikeda T; Ihn H
    Br J Dermatol; 2019 Sep; 181(3):505-511. PubMed ID: 30706452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokeratin 19 fragment 21-1 is a useful tumor marker for the assessment of extramammary Paget's disease.
    Kato J; Sumikawa Y; Hida T; Kamiya T; Horimoto K; Kamiya S; Sato S; Takahashi H; Sawada M; Yamashita T
    J Dermatol; 2017 Jun; 44(6):666-670. PubMed ID: 28150330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined serum carcinoembryonic antigen and cytokeratin 19 fragment levels provide a sensitive biomarker for lymph node metastasis in extramammary Paget's disease.
    Kato H; Nakamura M; Watanabe S; Oda T; Morita A
    J Dermatol; 2020 Jul; 47(7):763-769. PubMed ID: 32415799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring serum cytokeratin 19 fragment 21-1 to determine the efficacy of docetaxel chemotherapy in advanced extramammary Paget's disease.
    Onishi M; Maeda F; Akasaka T; Amano H
    J Dermatol; 2019 Mar; 46(3):e83-e84. PubMed ID: 30194782
    [No Abstract]   [Full Text] [Related]  

  • 7. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
    Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
    Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CYFRA 21-1 and CEA as prognostic and predictive markers in locally advanced and metastatic gastric carcinoma.
    Gopal V; Nisha Y; Ganesan P; Kayal S; Bobby Z; Adithan S; Penumadu P; Ramakrishnalay VP; Bandlamudi BP; Bahttacharjee A; Dahagama S; Dubashi B
    J Cancer Res Ther; 2024 Jul; 20(5):1412-1419. PubMed ID: 38261458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors of Extramammary Paget's Disease.
    Hatta N
    Curr Treat Options Oncol; 2018 Aug; 19(10):47. PubMed ID: 30112691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
    Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
    Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget's Disease.
    Urano-Takaoka M; Sumida H; Miyagawa T; Awaji K; Nagai K; Omatsu J; Miyake T; Sato S
    Acta Derm Venereol; 2022 Jan; 102():adv00636. PubMed ID: 34904690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary invasive extramammary Paget disease on penoscrotum: a clinicopathological analysis of 41 cases.
    Shu B; Shen XX; Chen P; Fang XZ; Guo YL; Kong YY
    Hum Pathol; 2016 Jan; 47(1):70-7. PubMed ID: 26508372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
    Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
    Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease.
    Zhu Y; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Mao HR
    Br J Dermatol; 2009 Sep; 161(3):577-82. PubMed ID: 19438449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
    Kibbi N; Owen JL; Worley B; Wang JX; Harikumar V; Downing MB; Aasi SZ; Aung PP; Barker CA; Bolotin D; Bordeaux JS; Cartee TV; Chandra S; Cho NL; Choi JN; Chung KY; Cliby WA; Dorigo O; Eisen DB; Fujisawa Y; Golda N; Halfdanarson TR; Iavazzo C; Jiang SIB; Kanitakis J; Khan A; Kim JYS; Kuzel TM; Lawrence N; Leitao MM; MacLean AB; Maher IA; Mittal BB; Nehal KS; Ozog DM; Pettaway CA; Ross JS; Rossi AM; Servaes S; Solomon MJ; Thomas VD; Tolia M; Voelzke BB; Waldman A; Wong MK; Zhou Y; Arai N; Brackett A; Ibrahim SA; Kang BY; Poon E; Alam M
    JAMA Oncol; 2022 Apr; 8(4):618-628. PubMed ID: 35050310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
    Gwak HK; Lee JH; Park SG
    Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
    Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
    Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.